OXFORD BIOMEDICA SOLUTIONS

Live / Registered — Registered (as of 11 Feb 2025)

What this means for you

Registered since 11 Feb 2025. The owner can stop confusingly similar uses in the classes it covers.

Record

Serial number
97361222
Registration number
7683508
Mark type
Stylized text
Filed
13 Apr 2022
Published for opposition
31 Oct 2023
Registered
11 Feb 2025
Attorney of record
Roberta S. Bren

Goods and services

  • Class 005 — Pharmaceuticals: Pharmaceutical preparations, biological preparations and gene therapy products in the nature of pharmaceutical and biological preparations for the treatment of genetic disorders and diseases, vaccines; pharmaceutical substances and preparations for the treatment or prevention of cancer, infectious disease, fungal diseases, disease caused by bacteria, viruses and parasites, eye disease, diseases of the central and peripheral nervous systems, cardiovascular disease, diseases affecting the immune system, inflammatory diseases, inherited disease, single gene disorders, diseases of the mouth, teeth, skin, hair and ear, bone and blood diseases and reproductive system disorders; gene therapy products, namely, nanoparticles, viral vectors, retroviral vectors, lentiviral vectors and non-viral vectors for the delivery of genes to cells, all for medical purposes; vaccine manufacturing preparations; viral vaccines, namely, viral vector, retroviral vector, lentiviral vector and non-viral vector preparations for the treatment or prevention of cancer, infectious disease, fungal diseases, disease caused by bacteria, viruses and parasites, eye disease, diseases of the central and peripheral nervous systems, cardiovascular disease, diseases affecting the immune system, inflammatory diseases, inherited disease, single gene disorders, diseases of the mouth, teeth, skin, hair and ear, bone and blood diseases and reproductive system disorders; biochemical and chemical products for use in medical science, namely, viral vectors; pharmaceutical and biochemical preparations for the treatment or prevention of cancer, infectious disease, fungal diseases, disease caused by parasites, eye disease, diseases of the central and peripheral nervous systems, cardiovascular disease, diseases affecting the immune system, inflammatory diseases, inherited disease, single gene disorders, diseases of the mouth, teeth, skin, hair and ear, bone and blood diseases and reproductive system disorders; pharmaceutical and biochemical preparations for contraceptive purposes
  • Class 040 — Treatment of materials: Custom manufacture of products relating to biotechnology; manufacture of gene therapy, and viral, retroviral, lentiviral and non-viral preparations and biopharmaceutical products; manufacture of biotechnology products; manufacture of viral and non-viral vectors; manufacture of vaccines
  • Class 042 — Scientific and technological services: Scientific research and development services in the field of biochemistry and genetic engineering; biochemistry engineering; genetic engineering; design of manufacturing facilities; quality control for others; scientific and technological services, namely, testing and validation services in the fields of gene and cell therapy and biotechnology; product development consultancy in the field of nanotechnology, gene therapy and vector-based delivery systems; medical and scientific laboratory services; scientific and technological services, namely, scientific research, development and analysis in the fields of gene and cell therapy and biotechnology; industrial analysis services, namely, analysis of viral vectors and gene therapy products to assure compliance with medical and pharmaceutical industry standards; provision of scientific information in the field of biotechnology, gene therapy and cell therapy; research and scientific analysis relating to drug discovery and development for others; scientific research in the nature of conducting clinical trials for others; manufacture of viral vectors, gene therapy and cell therapy products; product and manufacturing process development in the fields of biotechnology, gene therapy and cell therapy
  • Class 044 — Medical, beauty and agricultural services: Medical diagnostic testing; information relating to pharmaceuticals, bioceuticals and advanced therapy medicinal products; providing medical information to medical professionals in the form of reports in the field of biotechnology, gene therapy and cell therapy; consultancy, advice and information in the field of clinical trials, healthcare, pharmaceuticals and advanced therapy medicinal products; medical advisory services relating to vaccination regimes; medical advisory services relating to the treatment, relief and/or prevention of cancer, infectious diseases, fungal diseases, disease caused by parasites, eye disease, diseases of the central and peripheral nervous systems, cardiovascular disease, diseases affecting the immune system, inflammatory diseases, single gene disorders, diseases of the mouth, teeth, skin, hair and ear, bone and blood diseases, reproductive system disorders, and pharmaceutical and biochemical preparations for contraceptive purposes, in humans and animals
  • Class 045 — Legal and security services: Preparation and review of reports for regulatory approval of pharmaceuticals and bioceuticals; licensing of intellectual property; regulatory compliance consulting in the field of chemistry manufacturing and controls (CMC) activities

Owner

Prosecution history

  • 11 Feb 2025 — NOTICE OF REGISTRATION CONFIRMATION EMAILED
  • 11 Feb 2025 — REGISTERED-PRINCIPAL REGISTER
  • 17 Jan 2025 — 1(B) BASIS DELETED; PROCEED TO REGISTRATION
  • 24 Jun 2024 — NOTICE OF ALLOWANCE CANCELLED
  • 24 Jun 2024 — TEAS DELETE 1(B) BASIS RECEIVED
  • 26 Dec 2023 — NOA E-MAILED - SOU REQUIRED FROM APPLICANT
  • 31 Oct 2023 — OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
  • 31 Oct 2023 — PUBLISHED FOR OPPOSITION
  • 11 Oct 2023 — NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
  • 20 Sept 2023 — APPROVED FOR PUB - PRINCIPAL REGISTER
  • 14 Sept 2023 — TEAS/EMAIL CORRESPONDENCE ENTERED
  • 14 Sept 2023 — CORRESPONDENCE RECEIVED IN LAW OFFICE
  • 14 Sept 2023 — ASSIGNED TO LIE
  • 28 Apr 2023 — TEAS RESPONSE TO OFFICE ACTION RECEIVED
  • 03 Feb 2023 — NOTIFICATION OF NON-FINAL ACTION E-MAILED

View this trademark record on Marksy